After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...

-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read the Q1 sector assessment here.

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

In this article, we will be taking a look at the 10 Best Biotech Stocks Under $10 to Buy. According to Eli Casdin, CEO of ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

When Grammy-nominated singer-songwriter Aloe Blacc got COVID despite being vaccinated and boosted, he tried to fund research for a better solution. What he quickly found out? You can’t just write a ...

PDS Biotech has released data from the Phase II investigator-led colorectal cancer trial.

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...